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BACKGROUND: Previous trials have shown that pridopidine might reduce motor
impairment in patients with Huntington's disease. The aim of this study was to
ascertain whether higher doses of pridopidine than previously tested reduce motor
symptoms in a dose-dependent manner while maintaining acceptable safety and
tolerability.
METHODS: PRIDE-HD was a randomised, placebo-controlled, phase 2, dose-ranging
study in adults (aged ≥21 years) with Huntington's disease at outpatient clinics in 53
sites across 12 countries (Australia, Austria, Canada, Denmark, France, Germany,
Italy, Poland, Russia, the Netherlands, the UK, and the USA). Eligible patients had
clinical onset after age 18 years, 36 or more cytosine-adenine-guanine repeats in the
huntingtin gene, motor symptoms (Unified Huntington's Disease Rating Scale total
motor score [UHDRS-TMS] ≥25 points), and reduced independence (UHDRS
independence score ≤90%). Patients were randomly assigned (1:1:1:1:1) with
centralised interactive-response technology to receive one of four doses of
pridopidine (45, 67·5, 90, or 112·5 mg) or placebo orally twice a day for 52 weeks.
Randomisation was stratified within centres by neuroleptic drug use. The primary
efficacy endpoint was change in the UHDRS-TMS from baseline to 26 weeks, which
was assessed in all randomised patients who received at least one dose of study drug
and had at least one post-baseline efficacy assessment (full analysis set). Participants
and investigators were masked to treatment assignment. This trial is registered with
EudraCT (2013-001888-23) and ClinicalTrials.gov (NCT02006472).
FINDINGS: Between Feb 13, 2014, and July 5, 2016, 408 patients were enrolled and
randomly assigned to receive placebo (n=82) or pridopidine 45 mg (n=81), 67·5 mg
(n=82), 90 mg (n=81), or 112·5 mg (n=82) twice daily for 26 weeks. The full analysis
set included 397 patients (81 in the placebo group, 75 in the 45 mg group, 79 in the
67·5 mg group, 81 in the 90 mg group, and 81 in the 112·5 mg group). Pridopidine
did not significantly change the UHDRS-TMS at 26 weeks compared with placebo at
any dose. The most frequent adverse events across all groups were diarrhoea,
vomiting, nasopharyngitis, falls, headache, insomnia, and anxiety. The most common
treatment-related adverse events were insomnia, diarrhoea, nausea, and dizziness.
Serious adverse events occurred in the pridopidine groups only and were most
frequently falls (n=5), suicide attempt (n=4), suicidal ideation (n=3), head injury
(n=3), and aspiration pneumonia (n=3). No new safety or tolerability concerns
emerged in this study. One death in the pridopidine 112·5 mg group due to aspiration
pneumonia was considered to be possibly related to the study drug.
INTERPRETATION: Pridopidine did not improve the UHDRS-TMS at week 26
compared with placebo and, thus, the results of secondary or tertiary analyses in
previous trials were not replicated. A potentially strong placebo effect needs to be
ruled out in future studies.
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